Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin

Implications for monoclonal antibody therapy

Edward Neuwelt, H. D. Specht, S. A. Hill

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The variable penetration of chemotherapeutic drugs into brain and tumor is more dependent upon lipid solubility than upon size. In contrast, the molecular weight of virus- and tumor-specific monoclonal antibodies appears to limit uptake. The authors have studied eight patients with malignant brain tumors in order to compare tumor uptake of an iodinated contrast agent evaluated by computerized tomography scanning with uptake of the low and high molecular weight imaging agents technetium-99m (99mTc)-glucoheptonate and 99mTc-albumin, respectively, measured by radionuclide brain scanning. The agent 99mTc-labeled albumin was chosen for evaluation because its molecular weight (68,000) is similar to that of the most clinically promising monoclonal antibody fragment, the immunoglobulin (Ig) G Fab monomeric fragment. The radionuclide brain scans in the eight patients showed highly variable permeability of brain tumor to these markers, with uptake of the high molecular weight marker in the tumor being much less than that of the low molecular weight radionuclide. A clinical implication of these studies is that the success of monoclonal antibody therapy in the treatment of malignant brain tumors may require techniques to increase permeability of the blood-brain barrier and blood-tumor barrier to protein.

Original languageEnglish (US)
Pages (from-to)194-198
Number of pages5
JournalJournal of Neurosurgery
Volume65
Issue number2
StatePublished - 1986

Fingerprint

Brain Neoplasms
Albumins
Permeability
Molecular Weight
Monoclonal Antibodies
Radioisotopes
Tumor Biomarkers
Therapeutics
Oncogenic Viruses
Immunoglobulin Fragments
Immunoglobulin Fab Fragments
Molecular Imaging
Technetium
Brain
Blood-Brain Barrier
Solubility
Contrast Media
Neoplasms
Immunoglobulin G
Tomography

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin : Implications for monoclonal antibody therapy. / Neuwelt, Edward; Specht, H. D.; Hill, S. A.

In: Journal of Neurosurgery, Vol. 65, No. 2, 1986, p. 194-198.

Research output: Contribution to journalArticle

@article{72371d704c744bada0a8f6e8de71a885,
title = "Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin: Implications for monoclonal antibody therapy",
abstract = "The variable penetration of chemotherapeutic drugs into brain and tumor is more dependent upon lipid solubility than upon size. In contrast, the molecular weight of virus- and tumor-specific monoclonal antibodies appears to limit uptake. The authors have studied eight patients with malignant brain tumors in order to compare tumor uptake of an iodinated contrast agent evaluated by computerized tomography scanning with uptake of the low and high molecular weight imaging agents technetium-99m (99mTc)-glucoheptonate and 99mTc-albumin, respectively, measured by radionuclide brain scanning. The agent 99mTc-labeled albumin was chosen for evaluation because its molecular weight (68,000) is similar to that of the most clinically promising monoclonal antibody fragment, the immunoglobulin (Ig) G Fab monomeric fragment. The radionuclide brain scans in the eight patients showed highly variable permeability of brain tumor to these markers, with uptake of the high molecular weight marker in the tumor being much less than that of the low molecular weight radionuclide. A clinical implication of these studies is that the success of monoclonal antibody therapy in the treatment of malignant brain tumors may require techniques to increase permeability of the blood-brain barrier and blood-tumor barrier to protein.",
author = "Edward Neuwelt and Specht, {H. D.} and Hill, {S. A.}",
year = "1986",
language = "English (US)",
volume = "65",
pages = "194--198",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - Permeability of human brain tumor to 99mTc-glucoheptonate and 99mTc-albumin

T2 - Implications for monoclonal antibody therapy

AU - Neuwelt, Edward

AU - Specht, H. D.

AU - Hill, S. A.

PY - 1986

Y1 - 1986

N2 - The variable penetration of chemotherapeutic drugs into brain and tumor is more dependent upon lipid solubility than upon size. In contrast, the molecular weight of virus- and tumor-specific monoclonal antibodies appears to limit uptake. The authors have studied eight patients with malignant brain tumors in order to compare tumor uptake of an iodinated contrast agent evaluated by computerized tomography scanning with uptake of the low and high molecular weight imaging agents technetium-99m (99mTc)-glucoheptonate and 99mTc-albumin, respectively, measured by radionuclide brain scanning. The agent 99mTc-labeled albumin was chosen for evaluation because its molecular weight (68,000) is similar to that of the most clinically promising monoclonal antibody fragment, the immunoglobulin (Ig) G Fab monomeric fragment. The radionuclide brain scans in the eight patients showed highly variable permeability of brain tumor to these markers, with uptake of the high molecular weight marker in the tumor being much less than that of the low molecular weight radionuclide. A clinical implication of these studies is that the success of monoclonal antibody therapy in the treatment of malignant brain tumors may require techniques to increase permeability of the blood-brain barrier and blood-tumor barrier to protein.

AB - The variable penetration of chemotherapeutic drugs into brain and tumor is more dependent upon lipid solubility than upon size. In contrast, the molecular weight of virus- and tumor-specific monoclonal antibodies appears to limit uptake. The authors have studied eight patients with malignant brain tumors in order to compare tumor uptake of an iodinated contrast agent evaluated by computerized tomography scanning with uptake of the low and high molecular weight imaging agents technetium-99m (99mTc)-glucoheptonate and 99mTc-albumin, respectively, measured by radionuclide brain scanning. The agent 99mTc-labeled albumin was chosen for evaluation because its molecular weight (68,000) is similar to that of the most clinically promising monoclonal antibody fragment, the immunoglobulin (Ig) G Fab monomeric fragment. The radionuclide brain scans in the eight patients showed highly variable permeability of brain tumor to these markers, with uptake of the high molecular weight marker in the tumor being much less than that of the low molecular weight radionuclide. A clinical implication of these studies is that the success of monoclonal antibody therapy in the treatment of malignant brain tumors may require techniques to increase permeability of the blood-brain barrier and blood-tumor barrier to protein.

UR - http://www.scopus.com/inward/record.url?scp=0022496307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022496307&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 194

EP - 198

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -